Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan Plus Pembrolizumab in Recurrent Ovarian Clear Cell Carcinoma
NCT07913568Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2027
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in ovarian clear cell carcinoma (OCCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT07913568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07913568.